Advertisement

Topics

Fosun and Shanghai Pharmas Competing for $700 Million Stake in US-based Arbor

02:17 EDT 12 Aug 2017 | ChinaBio Today

Shanghai Fosun Pharma is vying with Shanghai Pharma Holding in a battle to acquire a minority stake in Atlanta's Arbor Pharma, according to Bloomberg News. Apparently, US private equity company KKR has put its Arbor stake up for sale, with bids expected in the $600-$700 million range. Arbor makes both generic and patented drugs; it also has an active R&D program with seven candidates in clinical trials and another in pre-clinical development. KKR made an investment of undisclosed size in Arbor in late 2014. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (SHA: 601607)

Share this with colleagues:

Original Article: Fosun and Shanghai Pharmas Competing for $700 Million Stake in US-based Arbor

NEXT ARTICLE

More From BioPortfolio on "Fosun and Shanghai Pharmas Competing for $700 Million Stake in US-based Arbor"

Quick Search
Advertisement
 

Relevant Topics

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...